Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Pharma Strategy Will Remove Barriers And Bolster Competition

Proposals Promise ‘Targeted Policies’ To Boost Generics And Biosimilars

Executive Summary

The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.

You may also be interested in...

Major Review Of EU Pharmaceutical Legislation Kicks Off

The European Commission has launched the process for reshaping and addressing the long-standing weakness in the EU’s pharmaceutical legislation. It has listed in a roadmap the issues it wants to address as it considers policy options for reforms.

BGMA’s Smith Reflects On 25 Years Of Progress

As Warwick Smith steps down after 25 years as leader of the British Generic Manufacturers Association, he talks about how far the country’s off-patent industry has come over the last quarter-century – including the acceptance of generics, the advent of biosimilars, and how freedom of pricing has helped to keep costs low while maintaining sustainable pricing – in the first part of an exclusive interview with Generics Bulletin.

Still More To Be Done On European Biosimilars

Off-patent industry association Medicines for Europe has released a Biosimilar Market Review report that examines availability, pricing systems, retail markets, hospital tendering, reimbursement systems, healthcare practitioner-related policies, information and education around biosimilars in 26 European countries, concluding that “while progress has been made, it is clear much more can be done.” 

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts